Oral Anticoagulants Market

Increased blood thinners awareness and innovation to drive market growth

Increased awareness about cardiovascular health, as well as the corresponding increase in new therapeutic launches, is one of the crucial drivers of  market growth. Cardiovascular therapeutics entails a multifaceted approach that may result in various medications. Nonetheless, blood thinners are an essential part of that treatment regimen. Several key market leaders have introduced anticoagulants, addressing the critical needs of treatment in terms of blood clot prevention. For instance, Pfizer Inc and Bristol-Myers Squibb Company introduced the anticoagulant Eliquis (apixaban). The product sells well and has shown superior risk reductions compared to other drugs, propelling the oral anticoagulants market CAGR.

The high prevalence of cardiovascular diseases (CVD) worldwide and the increasing demand for suitable thinners are also important driving factors. Anticoagulants have undergone significant R&D advancements since they were first made available to the general public. Since then, several novel therapeutics have been introduced and have been incredibly successful, including novel oral anticoagulants (NOACs). Eliquis and Xarelto are now the two most important anticoagulants on the  market. A greater prevalence of generics and additionally anticipated launches of anticoagulant generics could hurt the market.

However, the nature of cardiovascular diseases (CVD) has rendered them nearly incurable, and the rising prevalence is worsening patients' treatment options. This market, which has several unmet medical needs, is anticipated to be another critical growth driver for the  oral anticoagulants market revenue.

Enhanced awareness and education regarding the risks associated with thromboembolic events are driving the Global Oral Anticoagulants Market Industry. Public health campaigns and healthcare provider initiatives are effectively informing patients about the importance of anticoagulant therapy in preventing strokes and other complications. This increased awareness is likely to lead to higher patient engagement in treatment decisions, thereby boosting the demand for oral anticoagulants. As a result, the market is expected to grow steadily, with projections indicating a significant increase in market size as more individuals seek preventive measures against thromboembolic disorders.

The global increase in the geriatric population is a significant factor driving the Global Oral Anticoagulants Market Industry. Older adults are at a higher risk for thromboembolic disorders, necessitating effective anticoagulation therapies. As the demographic shifts towards an aging population, healthcare systems are adapting to meet the growing demand for anticoagulants. This trend is particularly pronounced in developed regions, where the elderly population is projected to expand substantially. Consequently, the market is poised for growth, with the potential for increased revenues as healthcare providers prioritize anticoagulant therapies for this vulnerable demographic.

Innovations in drug development are significantly influencing the Global Oral Anticoagulants Market Industry. The introduction of novel oral anticoagulants (NOACs) has transformed treatment protocols, offering patients more effective and safer options compared to traditional anticoagulants. These advancements not only enhance patient compliance but also reduce the risk of adverse effects. As a result, the market is likely to experience a compound annual growth rate (CAGR) of 5.53% from 2025 to 2035. This growth is indicative of the pharmaceutical industry's commitment to research and development in anticoagulant therapies.

Regulatory support and timely approvals for new anticoagulant therapies are crucial drivers of the Global Oral Anticoagulants Market Industry. Regulatory agencies are increasingly recognizing the need for innovative treatments that address unmet medical needs in anticoagulation. This supportive environment facilitates the introduction of new oral anticoagulants, which are often more effective and easier to manage than traditional therapies. As a result, the market is likely to benefit from a steady influx of new products, contributing to its growth trajectory and enhancing treatment options available to healthcare providers and patients.

The increasing incidence of cardiovascular diseases globally is a primary driver of the Global Oral Anticoagulants Market Industry. As cardiovascular conditions such as atrial fibrillation and venous thromboembolism become more prevalent, the demand for effective anticoagulant therapies rises. In 2024, the market is projected to reach 24.8 USD Billion, reflecting the urgent need for innovative treatment options. This trend is expected to continue, with the market potentially expanding to 44.8 USD Billion by 2035, indicating a growing recognition of the importance of anticoagulants in managing cardiovascular health.

By Region, the study provides market insights into Europe, North America, Asia-Pacific, and the Rest of the World. The North America Oral Anticoagulants market accounted for USD 9.57 billion in 2022 and is anticipated to exhibit a significant CAGR growth over the study period. The high prevalence of cardiovascular diseases requiring anticoagulant treatment, combined with new product launches throughout the region, will drive the growth of the oral anticoagulants market. According to American Heart Association research in October 2021, roughly 2,300 Americans die each day from cardiovascular diseases, an average of one death every 38 seconds.

Additionally, the Centers for Disease Control & Prevention estimates that in February 2022, heart disease will be the leading cause of mortality in the United States, with about 659,000 deaths annually. This accounts for nearly 25% of all deaths in the United States. As a result of the rise in cardiovascular diseases, the demand for oral anticoagulants in the region is increasing, boosting the market.

Along with these factors, the market in North America is anticipated to grow during the forecast period due to rising research and development efforts, increased awareness, and the prevalence of risk factors like obesity and diabetes among the general populace.

Further, the major countries studied in the market report are the U.S., Germany, Canada, France, the UK, Italy, Japan, India, Australia, Spain, China, South Korea, and Brazil.

Figure 3 ORAL ANTICOAGULANTS MARKET SHARE BY REGION 2022 (%)

Source Primary Research, Secondary Research, Market Research Future Database, and Analyst Review

The European oral anticoagulants market has the second-largest market share due to the rising incidence of cardiovascular disease, increasing the use of blood-thinning medications. For instance, the European Cardiovascular Disease Statistics show that more than 45% of all deaths in Europe are attributable to cardiovascular disease. Moreover, the existence of top pharma and biotech companies involved in therapeutic development and well-established healthcare infrastructure is fueling the overall regional market's growth to a large extent. Further, the German oral anticoagulants market held the largest market share, and the UK oral anticoagulants market was the fastest-growing market in the European region.

The Asia-Pacific Oral Anticoagulants Market will likely grow at the fastest CAGR from 2024 - 2032. This region's increased awareness of cardiovascular diseases and rising disposable income drive market growth. There are many options for advanced anticoagulant drugs (also known as blood thinners) to help patients feel better due to the prevalence of cardiovascular diseases. Moreover, China’s oral anticoagulants market held the largest market share, and the Indian oral anticoagulants market was the fastest-growing market in the Asia-Pacific region.

Major market players have introduced oral anticoagulants to meet the urgent needs for treating blood clots. The oral anticoagulants industry is mature, with many generics available, particularly for older product launches. New entrants face challenges as they must adhere to all drug formulations created by various associations and refrain from deviating from them. The oral anticoagulants market’s major players, such as Pfizer (US), Abbott Laboratories (US), AstraZeneca Plc (UK), and others, are investing in R&D to increase the number of pipeline medications.

The oral anticoagulants industry has recently provided novel oral and topical drugs that offer some of the most significant advantages. Key players are also pursuing various strategic market developments initiative to expand their footprint, including new product introductions, contractual agreements, mergers and acquisitions, R&D investments, and collaborative projects with other organizations. Commercializing anticoagulant products is a priority for governments and private players. Additionally, oral anticoagulants industry manufacturers are concentrating on increasing their presence in developing nations like India, Brazil, South Africa, China, and Mexico to expand business operations and look for new markets.

Mylan N.V. is a multinational pharmaceutical company specializing in generic and specialty drugs. In addition to operating a manufacturing facility for active pharmaceutical ingredients, the company also manages a specialty division focusing on allergy, respiratory, and psychiatric therapies. Mylan N.V. declared it would pay Aspen USD 756 million in September 2020 to expand the sterile oral anticoagulants available in Europe. This agreement will assist the business in increasing its hospital clientele and accelerating the development of their biosimilars brand in Europe.

Also, Twist Bioscience, based in South San Francisco, is a public biotechnology company that produces synthetic DNA and DNA products for customers in various industries. In October 2021, Boehringer Ingelheim International GmbH and Twist Bioscience, a high-quality artificial DNA supplier, entered into a broad research partnership to use Twist Bioscience's proprietary antibody libraries to identify the therapeutic relationship of antibodies against various Boehringer Ingelheim targets.